Feasibility and safety of cangrelor in patients with suboptimal P2Y₁₂ inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry

A. Selvarajah¹, A. H. Tavenier¹, W. L. Bor², V. Houben³, S. Rasoul³, E. Kaplan⁴, K. Teeuwen⁵, S. H. Hofma⁶, E. Lipsic⁷, G. Amoroso⁸, M. A. H. van Leeuwen¹, J. M. ten Berg²,9, A. W. J. van ’t Hof¹,3,9 and R. S. Hermanides¹*

Abstract

Background: Despite the advances of potent oral P2Y₁₂ inhibitors, their onset of action is delayed, which might have a negative impact on clinical outcome in patients undergoing percutaneous coronary intervention (PCI). Trials conducted in the United States of America have identified cangrelor as a potent and rapid-acting intravenous P2Y₁₂ inhibitor, which has the potential of reducing ischemic events in these patients without an increase in the bleeding. As cangrelor is rarely used in The Netherlands, we conducted a nationwide registry to provide an insight into the use of cangrelor in the management of patients with suboptimal platelet inhibition undergoing (primary) PCI (the Dutch Cangrelor Registry).

Study design: The Cangrelor Registry is a prospective, observational, multicenter, single-arm registry with cangrelor administered pre-PCI in: (1) P2Y₁₂ naive patients with ad-hoc PCI, (2) patients with STEMI/NSTEMI with suboptimal P2Y₁₂ inhibition including (3) stable resuscitated/defibrillated patients with out-of-hospital cardiac arrest (OHCA) due to acute ischemia and (4) STEMI/NSTEMI patients with a high thrombotic burden. Primary endpoint is 48 h Net Adverse Clinical Events (NACE), which is a composite endpoint of all-cause death, recurrent myocardial infarction (MI), target vessel revascularization (TVR), stroke, stent thrombosis (ST) and BARC 2-3-5 bleeding.

Summary: The Dutch Cangrelor Registry will assess the feasibility and safety of cangrelor in patients with suboptimal P2Y₁₂ inhibition undergoing (primary) PCI in the setting of acute coronary syndrome (ACS) and stable coronary artery disease (CAD) in the Netherlands.

Keywords: Cangrelor, P2Y₁₂ inhibitors, Percutaneous coronary intervention, Platelet inhibition

Introduction

Oral dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y₁₂-receptor inhibitor, is the cornerstone of treatment in patients with an acute coronary syndrome (ACS) and stable coronary artery disease (CAD) undergoing (primary) percutaneous coronary intervention (PCI) to prevent adverse ischemic complications [1]. Clopidogrel as well as the stronger P2Y₁₂ inhibitors ticagrelor and prasugrel are the recommended and most commonly used oral P2Y₁₂ inhibitors in the Netherlands [2, 3]. Ticagrelor and prasugrel provide faster, more potent, and more consistent P2Y₁₂ inhibition compared with clopidogrel, and have been associated with a lower rate of adverse ischemic events.

*Correspondence: r.s.hermanides@isala.nl
¹ Department of Cardiology, Isala Hospital, Zwolle, The Netherlands
Full list of author information is available at the end of the article
Despite the advances of these stronger P2Y12 antagonists, all oral P2Y12 inhibitors pose a relatively slow onset of inhibition in the first hours after intake [6, 7]. In addition, P2Y12 inhibition by oral agents may be insufficient due to ST-segment Elevation Myocardial Infarction (STEMI)-induced selective shunting of blood to vital organs, which decreases gastro-intestinal perfusion with impaired absorption of the oral P2Y12 inhibitors as a result. The bioavailability of the oral agents is further reduced in the presence of vomiting of the loading dose or therapeutic hypothermia [8, 9]. Furthermore, concomitant administration of morphine or fentanyl for pain relief and an oral P2Y12 inhibitor, might lead to significantly reduced or delayed absorption of the latter [10–12]. Therefore, intravenous administration of a P2Y12 inhibitor might be beneficial to overcome the limitations of oral P2Y12 inhibitors and might bridge the gap to optimal platelet inhibition by oral P2Y12 inhibitors only.

Cangrelor, an intravenous adenosine diphosphate (ADP)-receptor antagonist, is a potent and rapidly acting P2Y12 inhibitor with fast reversible effects. Its clinical use has been studied in three large-scale trials in the setting of ACS, referred to as the CHAMPION (Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) trials [13–15]. In the CHAMPION-PHoenix trial with 11,145 patients undergoing elective or urgent revascularization, cangrelor showed a significant reduction of composite endpoint of all-cause mortality, myocardial infarction (MI), ischemia-driven revascularization, or stent thrombosis (ST) at 48 h (4.7% vs. 5.9%; P=0.005), without a significant increase in severe bleeding (0.16% vs. 0.11%; P=0.44), compared with clopidogrel without pre-treatment with cangrelor [16]. This was mainly driven by less MIs in the cangrelor group and was consistent among patients presenting with STEMI, non-ST-segment elevation myocardial infarction (NSTEMI), and those presenting with stable CAD. The CHAMPION-PCI trial, in which cangrelor was compared with pre-interventional administered clopidogrel, also showed no significant difference in GUSTO-defined major bleeding between the two agents [17]. However, it failed to show superiority of the addition of cangrelor to clopidogrel with regard to ischemic events in patients with ACS and stable CAD compared to clopidogrel only. The same applied for the CHAMPION-PLATFORM trial, in which cangrelor was compared with post-interventional administered clopidogrel [18]. It showed only a significant reduction of death by all causes and ST in the subgroup of NSTEMI. Though, a pooled analysis of all 3 CHAMPION trials showed a reduction in peri-procedural ischemic complications in patients undergoing PCI at the expense of a small increase in mild bleeding [19].

Limited data is available about the stronger P2Y12 inhibitors, ticagrelor and prasugrel, in combination with cangrelor [20–22]. The CANTIC (Platelet Inhibitor with Cangrelor and Crushed Ticagrelor in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention) trial evaluated the additional effect of cangrelor with crushed ticagrelor in STEMI patients undergoing primary PCI and showed more potent platelet inhibitory effects with reduction of platelet reactivity as early as 5 min after cangrelor infusion compared with crushed ticagrelor alone [23]. The FABULOUS FASTER trial was the first randomized study to directly compare the pharmacodynamic effects of cangrelor with prasugrel and tirofiban. Tirofiban, another intravenous antiplatelet drug which belongs to the class of Glycoprotein IIb/IIIa inhibitors (GPIs), yielded superior inhibition of platelet aggregation (IPA) over cangrelor at 30 min after infusion. However, cangrelor and tirofiban were both superior to chewed prasugrel [41].

Since various studies have been conducted with cangrelor, there is little real-life data on the use of cangrelor in daily clinical practice. Hence, we propose a registry in the Netherlands, studying the feasibility and safety of cangrelor in high thrombotic risk patients with suboptimal P2Y12 inhibition who undergo primary (PCI).

**Methods**

**Study design**

The Cangrelor Registry is an open-label, prospective, multicenter, single-arm study which aims to assess the feasibility and safety of cangrelor in high thrombotic risk patients with suboptimal P2Y12 inhibition who undergo PCI.

The study will be conducted in 8 centers in the Netherlands: Isala Hospital (Zwolle), St. Antonius Hospital (Nieuwegein), Zuyderland Medical Center (Heerlen), Catharina Hospital (Eindhoven), Venlo VieCuri Medical Center (Venlo), OLVG (Amsterdam), University of Medical Center Groningen (Groningen), and Medical Center Leeuwarden (Leeuwarden). The study complies with the Declaration of Helsinki and is approved by the institutional review board (local medical ethics committee).

All patients, except resuscitated patients from cardiac arrest, will provide verbal informed consent for the participation prior to coronary angiography. Written informed consent will be obtained after the PCI. In the case of OHCA patients, their legal representative will be informed by the interventional cardiologist and will sign the informed consent on behalf of the patient.
Study protocol, patient enrollment and follow up
On admission, the medical team will perform physical examination, register vital parameters, electrocardiogram and laboratory assessments, and will set the diagnosis. All consecutive patients who fulfill the inclusion and exclusion criteria will be eligible for enrollment. Table 1 summarizes the inclusion and exclusion criteria. The indication for cangrelor and actual enrollment will be at the discretion of the treating physician. The timing of administration of cangrelor during the procedure is pre-specified: cangrelor bolus and infusion will be administered after initial coronary angiography, but before the start of PCI. PCI will be performed according to standard procedures. During the PCI, the initial Thrombolysis In Myocardial Infarction (TIMI) flow, TIMI flow post-PCI and myocardial blush grade (MBG) will be noted.

After PCI, adverse events will be assessed at 48 h and 30 days post-PCI. At 48 h after PCI, the electronic medical records will be consulted to assess the occurrence of any adverse events. Since most resuscitated patients will still be hospitalized at 48 h, the electronic medical records will be sufficient to determine the adverse events in these patients. If the medical records are insufficient, then a telephone evaluation with the patient will be conducted. The 30 days follow up will be performed by a telephone interview.

Pharmacological treatment
STEMI patients will receive concomitant medication according to European Guidelines including intravenous acetylsalicylic acid 500 mg, an oral loading dose of 180 mg of ticagrelor, 600 mg of clopidogrel or 60 mg of prasugrel, and an intravenous bolus of 5000 units of heparin, by the paramedical team (i.e. ambulance) or the medical team before the primary PCI. NSTEMI patients will receive intravenous acetylsalicylic acid 500 mg, an oral loading dose of 180 mg of ticagrelor, 600 mg of clopidogrel or 60 mg of prasugrel, and subcutaneous fondaparinux 1.5 mg or 2.5 mg till the coronary angiography. STEMI/NSTEMI patients with expected suboptimal P2Y12 inhibition and/or with high thrombus burden will receive cangrelor bolus and infusion before wire passage of the culprit lesion.

Patients with stable CAD awaiting coronary angiography will be on aspirin 80 mg per day. After PCI, they will receive an oral loading dose of ticagrelor, clopidogrel or prasugrel.

Table 1 Overview of inclusion and exclusion criteria

| Inclusion criteria                                                                 |
|------------------------------------------------------------------------------------|
| Age > 18 years                                                                      |
| Able to give informed consent                                                      |
| One of the following criteria:                                                     |
| Patients naive for P2Y12 inhibition undergoing ad-hoc PCI                          |
| Patients with STEMI/NSTEMI loaded with oral P2Y12 inhibitors though platelet inhibition still insufficient (< 2 h after oral loading dose) according to operator |
| Patients with STEMI/NSTEMI who vomited after P2Y12 loading dose                     |
| Patients with OHCA, based on VF/VT due to acute ischemia as the underlying cause, with Return of Spontaneous Circulation (ROSC) who have successfully been defibrillated and/or resuscitated with stable hemodynamics |
| STEMI/NSTEMI patients loaded with oral P2Y12 inhibitors with large thrombus burden (TBG 4 or 5) on initial coronary angiography and undergoing (primary) PCI with expected insufficient P2Y12 inhibition |

| Exclusion criteria                                                                 |
|------------------------------------------------------------------------------------|
| Patients on current/chronic treatment with P2Y12 inhibitors                        |
| Patients (pre)treated with GPIs                                                     |
| Patients with recent major bleeding complications or contraindication to DAPT.     |
| Hypersensitivity or allergy to and known contraindication to aspirin, clopidogrel, ticagrelor, prasugrel, or cangrelor |
| History of major clinical bleeding or known coagulopathy                           |
| Active bleeding                                                                     |
| History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke |
| Known severe liver dysfunction                                                      |
| Patients that have received any organ transplant or await any organ transplant       |
| Patients undergoing dialysis                                                       |
| Pregnant or lactating female                                                       |
| Patients currently participating in another investigational drug or drug-coated device study |

PCI, percutaneous coronary intervention; OHCA, Out of Hospital Cardiac Arrest; VF, ventricular fibrillation; VT, ventricular tachycardia; TBG, thrombus burden grade; GPI, Glycoprotein llb/llla inhibitor; DAPT, Dual antiplatelet therapy
Cangrelor
Cangrelor is a currently approved P2Y12-purinoreceptor antagonist, which is available for intravenous use in clinical care. It is a potent inhibitor of ADP-induced aggregation of human platelets, which acts directly at P2Y12-receptors and does not require conversion in the liver to an active metabolite, with rapid onset after intravenous infusion. Furthermore, plasma concentrations of cangrelor are unaffected by renal or hepatic impairment [42]. The short half-life of 3–6 min of cangrelor results in a rapid offset of antiplatelet effect and the effect on the bleeding time within 20 min after discontinuation of the infusion. Its advantages over an oral P2Y12 inhibitor include more potent and rapid P2Y12 inhibition and potentially lower bleeding risk.

Cangrelor is titrated on weight. First, a bolus of 30 µg/kg will be administered, then the infusion will be started based on 4 µg/kg/min. When transitioning to oral P2Y12 inhibitors, the loading dose of ticagrelor can be given at any time during the cangrelor infusion or immediately after discontinuation of the infusion [23]. The loading dose of clopidogrel or prasugrel will be given immediately after the discontinuation of the cangrelor infusion, because of drug-drug interaction [24]. Patients who vomited after an oral loading dose of ticagrelor results in a rapid offset of antiplatelet effect and the effect on the bleeding time within 20 min after discontinuation of the infusion. Its advantages over an oral P2Y12 inhibitor include more potent and rapid P2Y12 inhibition and potentially lower bleeding risk.

Endpoints
The primary endpoint is a composite efficacy and safety endpoint of all-cause mortality (including cardiac death), (recurrent) MI, target vessel revascularization (TVR), stroke, probable or definite ST and, bleeding (according to Bleeding Academic Research Consortium [BARC] type 2-3-5) at 48 h after (primary) PCI [25–27].

The secondary endpoint is the composite endpoint of all-cause mortality (including cardiac death), recurrent MI, target vessel revascularization (TVR), stroke, definite or probable ST, and bleeding (BARC type 2-3-5) at 30 days after (primary) PCI. Moreover, all individual endpoints will be assessed.

Sample size and statistical considerations
The current enrollment target is 250 patients across the 8 centers in the Netherlands. This is an observational study designed to provide descriptive summary information and therefore a comparison group is absent. As such, no formal power calculation has been performed. This size is considered as a good balance between feasibility to provide clinically meaningful information within the projected time period of 1 year.

Descriptive statistics will be performed for baseline characteristics and both primary and secondary endpoints. Continuous variables will be expressed as means with standard deviation, or as medians with 25th and 75th percentiles. Categorical variables will be expressed as frequencies with percentages.

Expected results
The Dutch Cangrelor Registry will explore the feasibility and safety of cangrelor in P2Y12 naive patients with ad-hoc PCI, in STEMI/NSTEMI patients with suboptimal P2Y12 inhibition including stable resuscitated/defibrillated patients with OHCA due to acute ischemia as the underlying cause, and/or in STEMI/NSTEMI patients with a high thrombotic burden, who all undergo (primary) PCI.

Discussion
The importance of optimal P2Y12 inhibition
(Primary) PCI with implantation of best in class drug-eluting stents (DESs) is the recommended treatment for flow restoration of an infarct-related artery in the setting of ACS or in patients with stable CAD with significant coronary artery stenosis [28]. Subsequently, intensive anti-thrombotic therapy with optimal P2Y12 inhibition through DAPT is crucial to prevent adverse ischemic complications with ST as most fierce complication.

Optimal P2Y12 inhibition in whom?
In particular, ACS patients with high thrombus burden (TIMI Thrombus Grade 4 or 5) with suboptimal P2Y12 inhibition are associated with a higher incidence of major adverse cardiovascular events (MACEs) [29–34]. Another example are the P2Y12 naive patients with stable CAD, who are considered for ad-hoc PCI. They are not able to receive immediate stenting due to the absence of P2Y12 inhibition and are once more exposed to contrast agents at the time of PCI. In these contexts, the use of a higher loading dose of oral P2Y12 inhibitors has been proven ineffective to facilitate potent P2Y12 inhibition, as well as crushing tablets which gives only approximately 2 h of gain of early P2Y12 inhibition compared with the oral agents [35, 36]. As a result, an intravenous P2Y12
inhibitor may bridge this gap to standard care with oral P2Y12 inhibitors and avoids postponing PCI. This also applies for defibrillated/resuscitated patients with PCI as a result of acute ischemia. The survivors of OHCA, whether conscious or comatose after ROSC, are not able to take oral P2Y12 inhibitors. Due to the need for nasogastric or orogastric tube insertion, there is an important delay until optimal P2Y12 inhibition is realized. Moreover, there are other factors that influence the pharmacokinetics of oral P2Y12 inhibitors, especially in comatose patients of OHCA, such as mild therapeutic hypothermia (MTH), gastroparesis, hypoperfusion of gastrointestinal tract and platelet hyperreactivity as a result of systemic inflammatory response syndrome (SIRS) [37]. These characteristics put this category of patients at risk of acute and subacute ST leading to increased morbidity and mortality. This underlines the continued unmet clinical need for a more potent, rapid-acting, and safe antiplatelet intravenous agent in patients undergoing PCI.

**Conclusion**

In the Dutch Cangrelor Registry, we aim to investigate the feasibility and safety of cangrelor in 250 patients with suboptimal P2Y12 inhibition undergoing (primary) PCI in daily clinical practice in 8 large interventional hospitals in the Netherlands.

**Abbreviations**

ACS: Acute Coronary Syndrome; ADP: Adenosine Diphosphate; AE: Adverse Event; AP: Angina pectoris; BARC: Bleeding Academic Research Consortium; CAD: Coronary artery disease; CABG: Coronary Artery Bypass Grafting; DAPT: Dual antiplatelet therapy; GPI: Glycoprotein IIb/IIIa inhibitor; IPA: Inhibition of platelet aggregation; MI: Myocardial infarction; MTH: Mild therapeutic hypothermia; NACE: Net Adverse Clinical Events; NSTEMI: Non ST-segment Elevation Myocardial Infarction; OHCA: Out of Hospital Cardiac Arrest; PCI: Percutaneous coronary intervention; ROSC: Return of Spontaneous Circulation; SAE: Severe Adverse Event; SIRS: Systemic inflammatory response syndrome; ST: ST-elevation; TIMI: Thrombolysis in Myocardial Infarction.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

RH conceptualized and designed the study. RH acquired the funding and supervised the study. RH critically revised and approved the final version of the manuscript. AH conceptualized and designed the study. AH critically revised and approved the final version of the manuscript. JB conceptualized and designed the study. JB critically revised and approved the final version of the manuscript. ML critically revised the final version of the manuscript. AS coordinated the study. AS prepared the analysis design and Table 1 (inclusion-and exclusion criteria). AS prepared, organized and wrote the final manuscript. AT contributed to prepare the analysis design and critically reviewed the final version of the manuscript. WB critically revised the final version of the manuscript. VH critically revised the final version of the manuscript. VH critically revised the final version of the manuscript. SR critically revised the final version of the manuscript. EH critically revised the final version of the manuscript. KT critically revised the final version of the manuscript. SH critically revised the final version of the manuscript. GA critically revised the final version of the manuscript. EL critically revised the final version of the manuscript. KH critically revised the final version of the manuscript. AH critically revised the final version of the manuscript. Each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content as described above. All authors agreed to be accountable for all aspects of the work to ensure that questions related to the accuracy or integrity of any part of the work would be appropriately investigated and resolved. All authors read and approved the final manuscript.

**Funding**

This study was supported by Grupo Ferrer Internacional (Spain).

**Availability of data and materials**

All data that will generated and analyzed during this study will be published in the main article.

**Declarations**

**Ethics approval and consent to participate**

Ethical approval was obtained from the institutional ethics committees of each participating hospitals, and all patients will provide written informed consent for the participation.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Strengths and limitations**

Our study’s strength is that it represents patients in the daily clinical practice with wide inclusion criteria in a multicentre design. However, the registry has some limitations, as it is an open label trial with a small cohort of patients without a control group. Secondly, given the study’s observational nature, the results may be influenced by (unmeasured) confounding factors. Finally, worldwide differences in health care systems and the availability of cangrelor is a point of discussion.
Author details
1Department of Cardiology, Isala Hospital, Zwolle, The Netherlands. 2Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. 3Department of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands. 4Department of Cardiology, Venlo VanEuri Medical Center, Venlo, The Netherlands. 5Department of Cardiology, Catharina Hospital, Eindhoven, The Netherlands. 6Department of Cardiology, Medical Center Leeuwarden, Leeuwarden, The Netherlands. 7Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands. 8Department of Cardiology, OLVG Hospital, Amsterdam, The Netherlands. 9Cardiovascular Research Institute Maastricht (EARIM), Maastricht, The Netherlands.

Received: 13 January 2021 Accepted: 17 May 2021

Published online: 12 June 2021

References
1. Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol. 2017;14:361–79. https://doi.org/10.1038/nrcardio.2017.18.
2. Valgimigli M, Bueno H, Byrne RA, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart. 2017. https://doi.org/10.1003/eurheart.ehw419.
3. Levine GN, Bates ER, Blankenship JC, et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:2574–e651. https://dx.doi.org/10.1161/CIR.0b013e31823ba622.
4. Capadanno D, Alfonso F, Levine GN, et al. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018;72(pt 1A):2915–31. https://doi.org/10.1016/j.jacc.2018.09.057.
5. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy of acute coronary syndromes (PLATO): a randomized double blind study. Lancet. 2010;375:283–93.
6. Franchi F, Rollini F, Cho JR, et al. Impact of escalating loading dose of regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv. 2015;8:1457–67. https://dx.doi.org/10.1016/j.jcin.2015.02.030.
7. Alexopoulos D, Makris G, Xanthopoulou I, et al. Onset of antiplatelet activity with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamics study. Circ Cardiovasc Interv. 2014;7:233–9. https://dx.doi.org/10.1161/CIRCINTERVENTIONS.113.001118.
8. Heestermans AA, van Wermont JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 2008;122(6):76–81.
9. Soucikova L, Opatrlova R, Suk P, et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2013;69(3):309–17.
10. Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction; the randomized, double-blind, placebo-controlled IMPRESS trial. Eur Heart J. 2016;37(3):425–52.
11. Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-segment acute myocardial infarction undergoing primary percutaneous intervention. Circ Cardiovasc Interv. 2014;8(1):e001593.
12. McEvoy JW, Ibrahim K, Kickerl TS, et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous intervention: the PACIFY randomized clinical trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl). Circulation. 2018;137(3):307–9.
13. Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function sub-study from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012;34(1):44–55.
14. Ferreiro JL, Ueno M, Angiolillo DJ, et al. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther. 2009;7(10):1195–201.
15. Franchi F, Rollini F, Muniz-Lozano A, et al. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther. 2013;11(10):1279–91.
16. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303–13.
17. Harrington RA, Stone GW, Mc Nulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24):2318–29.
18. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI on ischemic events. N Engl J Med. 2009;361(24):2330–41.
19. Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2015;382(9909):1981–92.
20. Badreddin HA, Carter D, Cook BM, et al. Safety and tolerability of transitioning from cangrelor to ticagrelor in patients who underwent percutaneous coronary intervention. Am J Cardiol. 2017;120(3):359–61.
21. Schneider DJ, Seecheran N, Raza SS, et al. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015;26(1):42–8.
22. Schneider DJ, Agarwal Z, Seecheran N, et al. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014;7(4):435–42.
23. Franchi F, Rollini F, Rivas A, et al. Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention: the Cangrelor Versus Standard Therapy to Achieve Optimal Management of cangrelor and clopidogrel: the platelet function substudy from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012;34(1):44–55.
24. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute coronary infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–619.
25. Thuyesen K, Alpert JS, Jaffes AS, ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2018;40(3):237–69.
26. Utz DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.
27. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2376–47.
28. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute coronary infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–619.
29. Sianos G, Papafaklis MI, Daemen J, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007;50:573–83.
30. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303–13.
31. Fokkema ML, Vlaar PJ, Svilaas T, et al. Incidence and clinical consequences of distal embolization during primary angioplasty. Eur Heart J. 2007;28:1941–50.
34. Fukuda D, Tanaka A, Shimada K, et al. Predicting angiographic distal embolization following percutaneous coronary intervention in patients with acute myocardial infarction. Am J Cardiol. 2003;91:403–7.
35. Alexopoulos D, Bhatt DL, Hamm CW, et al. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap. Am Heart J. 2015;170:3–12.
36. Alexopoulos D, Barmpoutis N, Gkizas V, et al. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic/pharmacodynamic study. Clin Pharmacokinet. 2016;55:359–67.
37. Neylon A, Garot P, et al. Antiplatelet agents in out of hospital cardiac arrest survivors does an impaired biological response increase stent thrombosis risk? J Thorac Dis. 2016;8(9):E1090–2.
38. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265–74.
39. Safley DM, Venkitachalam L, Kennedy KF, Cohen DJ. Impact of glycoprotein IIb/IIIa inhibition in contemporary percutaneous coronary intervention for acute coronary syndromes: insights from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2015;8:1574–82.
40. Muñiz-Lozano A, Rollini F, Franchi F, Angiolillo DJ. Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice. Ther Adv Cardiovasc Dis. 2013;7:197–213.
41. Gargiulo G, Esposito G, et al. Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment–elevation myocardial infarction. Circulation. 2020;142(5):441–54.
42. Keating GM. Cangrelor: a review in percutaneous coronary intervention. Drugs. 2015;75(12):1425–34.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.